Mutation of p53 is a common feature of cancer. Breast cancer is the most common malignancy that develops in women; however, somatic mutation of p53 is rare, suggesting that p53 becomes inactivated by other mechanisms. p53 is expressed as smaller isoforms, some of which inhibit wild-type p53. There are no studies that have examined the relative expression of all isoforms in this disease. We have analysed the relative messenger RNA expression of the p53 isoforms, Δ40, Δ133, β and γ in a panel of 6 breast cancer cell lines, 148 breast cancers specimens and 31 matched normal adjacent tissues by semi-quantitative real-time reverse transcription-PCR and analysed their relationship to clinical features and outcome. We have identified several important clinical associations, particularly with Δ40p53, which was expressed at levels that were ~50-fold higher than the least expressed isoform p53γ. Δ40p53 was significantly upregulated in tumour tissue when compared with the normal breast and was significantly associated with an aggressive breast cancer subtype-triple negative. Additionally, p53β expression was significantly negatively associated with tumour size and positively associated with disease-free survival, where high levels of p53β were protective, particularly in patients with a mutation in p53, suggesting p53β may counteract the damage inflicted by mutant p53. In conclusion, the relative expression of p53 isoforms is related to clinical features of breast cancer and outcome. These results have implications for the stratification of breast cancer based on p53 function and may provide an alternate explanation for deregulated p53 signalling in breast cancer.
Introduction
The tumour suppressor, p53, is critical for the response to DNA damage and has been classified as the 'guardian of the genome', due to its ability to coordinate multiple and diverse signalling pathways involved in this response (1) (2) (3) . The importance of p53 in tumour suppression has long been established, with mutations arising in more than half of all human cancers (4) . The role of p53 in suppressing tumour growth is primarily due to its induction of cell cycle arrest and DNA repair or apoptosis, following genotoxic stress (1, 5) . However, in recent years, it has become apparent that mutations in the p53 gene can drive tumour migration and metastasis, suggesting that not only is inactivation of p53 critical for tumour initiation, it is also required for the acquisition and maintenance of an invasive cancer phenotype (6) (7) (8) (9) (10) (11) .
Breast cancer is the most common malignancy that develops in women, responsible for the highest cancer-associated death rates (12) . In breast cancer, somatic mutation of p53 is frequently associated with tumour progression, resistance to therapy and poor prognosis (4) . However, its mutation frequency (~25%) is less than would be expected for a protein that plays such a pivotal role in maintaining genomic integrity in the breast (4) . Moreover, many studies have shown a lack of association of breast cancer risk with polymorphisms in p53 and/or components of this signalling pathway (e.g. MDM-2) (13) , and p53-dysregulated gene expression signatures have been shown to be a better predictor of outcome and chemotherapy response than p53 mutation (3, 14, 15) , indicating that wild-type p53 (WTp53) becomes inactivated by mechanisms other than mutation.
In recent years, it has been demonstrated that p53 is expressed as 12 distinct smaller isoforms: p53, p53β, p53γ, Δ133p53, Δ133p53β, Δ133p53γ, Δ40p53, Δ40p53β, Δ40p53γ, Δ160p53, Δ160p53β and Δ160p53γ (16, 17) . The isoforms are produced through a combination of alternative promoter usage (Δ133, Δ160), alternative splicing (Δ40, β, γ) and alternative initiation of translation (Δ40, Δ160). Their functions and mechanisms of action are poorly understood and have been derived primarily from studies utilising overexpression in cell lines (16, (18) (19) (20) . Nevertheless, reports suggest that they can enhance or inhibit the ability of p53 to transactivate certain target promoters and to induce apoptosis (16, 18) . Thus, regulated expression of p53 isoforms is critical for the biological outcome of p53.
The expression of p53 isoforms has been shown to be dysregulated in several human cancer types (16, (21) (22) (23) (24) (25) , including breast cancer (26, 27) . There has been little progress in establishing the endogenous role of these isoforms in cancer due to a lack of available antibodies that can distinguish the isoforms from the WT protein and a lack of clinical specimens to examine their messenger RNA (mRNA) expression. However, there is emerging evidence that p53 isoforms are associated with prognosis and treatment response in cancer. In breast cancer patients with mutant (MT) p53, the presence of p53γ mRNA was associated with lower recurrence rates and higher overall survival rates, compared with patients who did not express p53γ (26) . Increased expression of p53β mRNA in ovarian and renal cell carcinoma was associated with worse prognosis and tumour grade, respectively (23, 24) . High Δ40p53 mRNA expression was shown to be independently associated with good prognosis in mucinous ovarian cancer (28) . Furthermore, in leukaemia, the relative expression of p53β has been inversely correlated with chemotherapy response (21) , whereas our own studies have shown that p53β was upregulated by cisplatin in melanoma (25) . This suggests that the ratio of p53 isoforms to WTp53 is important in cancer prognostication and may be involved in the response to therapy.
There is a particular paucity of studies that have analysed the relative expression of p53 isoforms in breast cancer. All studies to date have determined the expression of p53 isoforms using nested reverse transcription-PCR (RT-PCR) (16, 26, 27) , which is not a quantitative technique. As a result, there is no quantitative information on which isoforms are most highly expressed and are therefore more likely to alter p53 function and to have prognostic significance in breast cancer. This study has analysed mRNA expression of the Δ40, Δ133, β and γ p53 isoforms in 6 breast cancer cell lines and 148 invasive breast cancers. p53 isoforms in breast cancer diagnoses and patient information is described in Supplementary Table S1 , available at Carcinogenesis Online. An additional cohort of 14 Grade 3 oestrogen receptor negative (ER−), progesterone receptor negative (PR−), human epidermal growth factor receptor negative (HER2−) breast tumours was used in validation studies. This study complies with the Helsinki Declaration with ethical approval from the Hunter New England Human Research Ethics Committee (approval number: 09/05/20/5.02). All patients have consented to their tissue and clinical information being used in this study.
Cell lines
Cell pellets were kindly provided for a panel of breast cancer cell lines MCF-7, T-47D, ZR-75-1, MDA-MB-231, MDA-MB-468, Du4475 and HMT-3522-T42 and the non-tumourigenic cell lines HMT-3522-S2 and HMEC by Dr N.Verrills and Dr J.Weidenhofer, University of Newcastle, Newcastle, NSW, Australia.
Extraction of RNA
Total RNA was extracted from fresh frozen normal adjacent tissue using the RNeasy Mini Kit (Qiagen, Doncaster, VIC, Australia). RNA was quantified using the Quant-it RiboGreen RNA Assay Kit (Life Technologies, Mulgrave, VIC, Australia) and purity assessed by A 260/A280 ratios (>1.8) using the Nanodrop (Thermo Scientific, Wilmington, DE). The RNA integrity of tumour samples was analysed using the 2100 Bioanalyser and the RNA 6000 Nano Kit (Agilent Technologies, Mulgrave, VIC, Australia), and all samples used in this analysis had an RNA integrity number of 8 or greater.
Semi-quantitative real-time-PCR
Total RNA (660 ng) was reverse transcribed to generate complementary DNA (cDNA) using the High Capacity cDNA Reverse Transcription Kit (Life Technologies) according to the manufacturers' instructions. Real-time PCR analysis was performed in triplicate using TaqMan® Universal PCR mix (Life Technologies) on 20 ng (tumour samples) or 10 ng (cell lines) of cDNA according to the manufacturers' instructions, with results quantified on a 7500 real-time PCR system (Life Technologies). The expression of the following p53 isoform transcripts was analysed: p53β, p53γ, Δ40p53 and Δ133p53 using the primer/probes shown in Supplementary Table S2 , available at Carcinogenesis Online. In addition, Taqman Gene Expression Assays for β-actin (Human ACTB Endogenous Control) and β2-microglobulin (assay ID: Hs99999907_m1) were also used (Life Technologies). PCR reactions containing no cDNA and no reverse transcriptase were included in every PCR run. cDNA from MCF-7 cells was used as a normalizer in each individual plate to account for variation between PCR runs. Any gene that had a Ct value >35 was classed as not expressed in that sample. The relative expression of the p53 isoform transcripts was normalized to β-actin (ΔCt) and expressed as the fold change calculated using the 2 −∆∆Ct method as described previously (29) . The relative expression of β-actin in tumours was not significantly different between the subgroups analysed and therefore served as an appropriate normalizer for this analysis. β2-Microglobulin was used as a normalizer in NAT versus tumour comparisons.
Western blotting
Protein extraction, separation by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, and western blot analysis of cell lines to determine the expression of WTp53 and its isoforms was performed as described previously (29) . The mouse monoclonal antibodies used for the detection of p53 (DO1, 1 µg/ml; 1801, 7.5 µg/ml) were purchased from Merck Millipore (Darmstadt, Germany). The rabbit monoclonal antibody used for the detection of glyceraldehyde-3-phosphate dehydrogenase (clone EPR6256) was purchased from Abcam (Cambridge, England). Results were visualized and quantitated on an Odyssey CLx fluorescent Imager (LI-COR, Lincoln, NE).
p53 mutation analysis DNA derived from tumour tissue was used to determine the presence of p53 mutations in cases where available (139 cases). All 11 exons (including the intron/exon boundaries) of the TP53 gene were analysed by dideoxy sequencing of the respective PCR products. PCR products were bi-directionally sequenced with the BigDye® Terminator version 3.1 Cycle Sequencing Kit and size separated by capillary electrophoresis using an ABI3730 DNA Analyser (Life Technologies) as described previously (25, 30) . Sequencing traces were analysed using Mutation Surveyor version 3.00 (SoftGenetics®, State College, PA). Mutations were described using the nomenclature guidelines of the Human Genome Variation Society (http://www.hgvs.org). The DNA sequence numbering is based on the cDNA sequence for p53 (NCBI RefSeq NM_000546.4). Non-synonymous and synonymous variants were run through the SIFT predictive algorithm for amino acid substitution and functional prediction (31,32) as described previously (30) .
Statistical analysis
Analysis of p53 isoform expression in breast cancer tissues and cell lines. The normality of the data distribution was tested using a D'Agostino and Pearson Omnibus test. The values showed that not all groups (depending on the comparison) had been sampled from a Gaussian distribution. Therefore, samples were log transformed to distribute the data normally, prior to statistical analysis. A two-tailed t-test was used to determine if there was a statistically significant difference in the expression of p53 isoforms between any two subgroups. One-way analysis of variance test followed by a Tukey multiple correction test was used to determine the statistical significance of p53 isoform transcript expression between multiple (>2) subgroups. Analysis of the correlation of p53 isoform mRNA expression with one another was performed using Spearman's correlation test. Pearson's chi-square test was used to evaluate the distributions of the clinical parameters examined between tumours with and without p53 mutations. Analysis of p53 isoform expression in relation to clinical features. The relationship between p53 isoform expression and clinical parameters was interrogated using multiple linear regression, which adjusts for possible confounding variables that may affect the relative expression of the p53 isoforms. To adjust for heterogeneity in the sample distribution samples were ln transformed. For the analysis of patients of all grades, where p53 isoform expression was the response variable, the model took into account the following confounding variables: Age at diagnosis + Grade + p53 mutation + lymph node (LN) positivity + Tumour size. For the analysis of hormone receptor expression, only Grade 3 patients were analysed as this was the only grade that contained tumour specimens that were ER negative within the cohort, the model took into account the following confounding variables: Age at diagnosis + p53 mutation + LN positivity + Tumour size + Receptor status. In the tables summarising the multiple linear regression, the adjusted estimate indicates the mean change in isoform expression for every unit change in the predictor, where a negative value indicates a decrease and a positive value indicates an increase.
Survival analysis
Kaplan-Meier survival curves were generated to compare the development of metastases following diagnosis in relation to p53 isoform expression and p53 mutation. The primary outcome of this analysis was disease-free survival. Comparison of survival curves was performed using the log-rank (Mantel-Cox) test.
All statistical analyses were performed using GraphPad Prism (Version 5.04) software (GraphPad Software, La Jolla, CA) and SAS version 9.3 (SAS Institute, Cary, NC). A P-value of <0.05 was considered to be statistically significant.
Results

Δ40p53 is the highest expressed p53 isoform in breast cancer
To determine which p53 isoform was the highest expressed in breast cancer, the mRNA expression of Δ40p53, Δ133p53, p53β and p53γ was analysed by real-time RT-PCR in 148 breast cancer tissues. The analysis showed that Δ40p53 was the highest expressed isoform in breast cancer tissues ( Figure 1A ). Δ40p53 mRNA was expressed at levels that were 49.8× higher than the median expression of the least expressed isoform p53γ, and at levels that were 33.7× and 15.5× higher than Δ133p53 and p53β, respectively ( Figure 1A ). Although the relative expression levels were remarkably reduced for the Δ133p53, p53β and p53γ isoforms when compared with Δ40p53, Spearman rank analysis showed that the relative expression of each isoform within the tumours was highly correlated with one another ( Supplementary  Table S3 , available at Carcinogenesis Online). Analysis of p53 isoform mRNA expression in a panel of breast cancer cell lines confirmed that Δ40p53 was the highest expressed isoform, with similar relative expression patterns as found in breast cancer tissues ( Figure 1B ).
Δ40p53 is highly expressed in tumours when compared with normal breast tissue
Only one study to date has analysed p53 isoform mRNA expression in breast cancer compared with normal breast tissues (16) . However, the analysis was not quantitative and the expression in tumour samples was compared with a pool of normal breast specimens not allowing the frequency of p53 isoform expression to be determined. From these studies, the authors concluded that the expression of the p53 isoforms was not different in breast tumours compared with the normal breast (16) . Given that Δ40p53 was the highest expressed isoform in breast cancer tissues and cell lines, we aimed to determine its relative expression when compared with NAT. This analysis was performed on 31 patients for which NAT was available. In tumours, Δ40p53 mRNA was expressed at levels that were significantly (2.6×) higher than the median expression of matched NAT samples, with levels up to 240-fold higher in some tumour specimens ( Figure 1C ).
To confirm that Δ40p53 was expressed at the protein level, we analysed a panel of breast cancer cells containing WTp53 (MCF-7, ZR-75-1) or MT p53 (MDA-MB-231, T-47D, HMT-3522-T42) and two benign breast epithelial cell lines (HMT-3522-S2, HMEC) by western blotting (Figure 2 ). We used two different antibodies: DO1, which detects an epitope in the N-terminus (amino acids 20-25) and cannot recognize the N-terminally deleted p53 isoforms and 1801, which detects an epitope within the N-terminus (amino acids [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] and is capable of recognizing the Δ40p53 isoform. The 1801 antibody clearly detected p53 and a smaller molecular weight band of ~44-46 kDa, consistent with Δ40p53 ( Figure 2A ). This smaller band was not detected by the DO1 antibody (a very faint smaller band was detected by DO1 but its molecular weight was ~38 kDa). The Δ40p53 isoform was detected at the highest levels in the p53 MT cell lines (MDA-MB-231, T-47D, HMT-3522-T42) and was detected at lower levels in the WTp53 cell lines (MCF-7 and ZR-75-1). Its expression in breast cancer cell lines was significantly higher than that seen in the benign breast epithelial cell lines HMT-3522-S2 and HMEC, confirming our real-time PCR data that Δ40p53 is upregulated in breast cancer when compared with normal breast tissue (Figure 2A and B). The ratio of Δ40p53 to full-length p53 protein was variable between the cell lines examined, but Δ40p53 was shown to be higher than or equivalent to p53 in four of the seven cell lines examined (Figure 2A : MCF-7, ZR-75-1, HMT-T42, HMT-S2).
Given that Δ40p53 can also be generated by alternative initiation of translation (18, 33) , we next determined whether the mRNA expression of Δ40p53 was representative of its expression at the protein level. The mRNA levels of Δ40p53 were comparable with that observed at the protein level in the majority of the cell lines examined, suggesting that alternative splicing (rather than alternative initiation of translation) represents a major route of production of this isoform in breast cancer ( Figure 2B ). In comparison, p53 mRNA expression was much higher than its protein levels ( Figure 2C ). This was expected given that full-length p53 is predominantly regulated post-translationally and is much less stable than the Δ40p53 isoform, which lacks the MDM-2 binding domain and escapes the rapid MDM-2-dependent proteasomal degradation that full-length p53 is subject to (18, 33, 34) .
p53 isoform mRNA expression is not associated with p53 mutation status
To determine if p53 isoform expression was related to the mutation status of p53, the entire coding region (including intron/exon boundaries) of p53 was sequenced in cases where tumour DNA was available (139/148 cases). Deleterious mutations were present in 28.1% of the cohort ( Supplementary Table S4 , available at Carcinogenesis Online, and Table I) , where they were significantly associated with grade, LN status and hormone receptor status (Table I) . As expected, tumours positive for ER (20/105 cases analysed, 19%, Table I ) and PR (17/96 cases analysed, 17.7%, Table I) were less likely to have p53 mutations, whereas those that were HER2 positive (12/24 cases analysed, 50%, Table I ) or triple negative (ER−, PR−, HER2−; 10/18 cases analysed, 55%, Table I ) had a greater proportion of tumours containing p53 mutations.
We analysed whether the relative expression of the p53 isoforms was associated with deleterious mutations in p53 using multiple linear regression. The relative mRNA expression of the p53 isoforms was not associated with the mutation status of p53 (Table II) .
The expression of p53 isoforms is associated with clinical features
The relationship of the relative mRNA expression of the p53 isoforms to clinical features, including age at diagnosis, tumour size, LN status and grade was examined using multiple linear regression analysis. There was no significant difference in the relative expression of Δ40p53, Δ133p53, p53β and p53γ in relation to age at diagnosis or LN positivity (Table II) . However, p53β mRNA expression showed a significant negative association with tumour size (Table II , P = 0.0326) and p53γ mRNA expression was associated with tumour grade (Table  II , P = 0.0264), with Grade 3 tumours expressing significantly less p53γ mRNA compared with Grade 1 and 2 tumours (Supplementary Figure S1 , available at Carcinogenesis Online).
The expression of Δ40p53 is associated with HER2 status and the triple-negative phenotype We next determined if there was an association between p53 isoform expression and hormone receptor status. This analysis was performed using multiple linear regression on Grade 3 tumours (n = 72) as this was the only grade that contained tumour specimens that were ER negative within the cohort. Of the predictors included in this model, both age at diagnosis and tumour size were significantly negatively associated with p53β (Tables III and IV) .
We examined the relationship between the p53 isoforms and each of the receptors (ER, PR and HER2) individually. None of the isoforms showed any significant association with ER or PR (Table III) . Additionally, Δ133p53, p53β and p53γ were not significantly different in their relative expression level between tumours expressing HER2 and those that did not (Table III) . However, Δ40p53 was significantly negatively associated with HER2 positivity (P = 0.0021, Table III) , with its expression being significantly increased in HER2negative tumours when compared with HER2-positive tumours (Supplementary Figure S2 , available at Carcinogenesis Online).
The cohort was divided into eight distinct groups based on their receptor status (positive or negative) for the combination of ER, PR and HER2 (group 1: ER−, PR−, HER2−; group 2: ER− PR− HER2+; group 3: ER− PR+ HER2−; group 4: ER− PR+ HER2+; group 5: ER+ PR− HER2−; group 6: ER+ PR− HER2+; group 7: ER+ PR+ HER2− and group 8: ER+ PR+ HER2+). Δ133p53, p53β and p53γ showed no significant difference in their relative expression level between the eight groups (Table IV) . However, Δ40p53 was significantly associated with hormone receptor status (P = 0.0344), particularly in the triple-negative cohort (ER−, PR−, HER2−), where it was significantly increased by a factor of 1.114 when compared with those that were hormone receptor positive (ER+, PR+, HER2+; Table  IV , Supplementary Figure S2 , available at Carcinogenesis Online). We compared an independent group of 14 Grade 3 ER− PR− HER2− cases against the other 7 subgroups (n = 53) in an effort to validate the upregulation of Δ40p53 in this subgroup ( Supplementary Table  S5 , available at Carcinogenesis Online). We found that Δ40p53 was not significantly different in ER− PR− HER2− breast cancer cases ( Supplementary Table S5 , available at Carcinogenesis Online). However, we did not have p53 mutation data on these additional cases and, therefore, these cases could not be adjusted for p53 mutation status as in our original analysis (Table IV) . Given the high proportion of p53 mutations in our original cohort (52.6% of ER− PR− HER2− cases), we suspect that not adjusting for p53 mutations would be the main cause for this result.
Metastasis-free survival and p53 isoform expression
We next examined the relationship between p53 isoform expression and the development of metastases in 130 cases for which we had follow-up data. There was no difference in metastasis-free survival when cases expressing high levels (higher than the median) of Δ40p53, Δ133p53 or p53γ were compared with those expressing low levels of these p53 isoforms ( Figure 3A ). However, cases expressing low levels of p53β had significantly diminished metastasis-free survival than cases expressing high levels of p53β (log-rank test, P = 0.0434), suggesting that high levels of p53β may be protective against metastasis ( Figure 3A) .
We next determined the additive effect of having multiple p53 isoforms highly expressed on breast cancer metastasis. Metastasisfree survival was not different in cases expressing high levels (higher than the median) of multiple isoforms, compared with those expressing 0 or 1 isoform highly, suggesting that there is no additive effect ( Figure 3A) . Although metastasis-free and overall survival has been reported to be lower in breast cancer patients with p53 mutations (26, 35) , we observed no difference in metastasis-free survival when cases with p53 mutations were compared with those that did not harbour deleterious mutations in this study ( Figure 3B ). This is consistent with the heterogeneity in the relationship between p53 mutations and breast cancer prognosis (36) .
Bourdon et al. (26) have shown previously that in breast cancer patients with MT p53, the presence of p53γ mRNA was associated with lower recurrence rates and higher overall survival rates, compared with patients who did not express p53γ. Thus, we next determined the effect of high or low isoform expression in combination with a p53 mutation on metastasis-free survival. The expression of Δ40p53, p53γ or Δ133p53 did not alter metastasis-free survival in either p53 WT or MT patients ( Figure 3B ). In contrast, low expression of p53β in combination with a mutation in p53 significantly decreased metastasis-free survival (log-rank test, P = 0.0487; Figure 3B ). Metastasis-free survival of patients expressing high levels of p53β and carrying a mutation in p53 was similar to patients who did not contain p53 mutations ( Figure 3B ). This suggests that high levels of the β isoform in patients who have a mutation in p53 may counter the damage inflicted by MT p53. We were unable to study the relationship between overall survival and p53 isoform expression in this cohort, as there were only five disease-related deaths in the 130 patients analysed during this time period.
Discussion
The tumour suppressor p53 is critical for the response to DNA damage (1, 2, 37) . p53 isoforms represent critical regulators of p53 functional activity and there is emerging evidence that some isoforms play critical roles in cell growth and tumour suppression that are independent of full-length p53 (38) . However, there is a paucity of studies that have analysed the relative expression of p53 isoforms in breast cancer. Moreover, to the best of our knowledge, there have been no studies that have analysed all the p53 mRNA variants in breast cancer within the same study. This study has analysed the relative mRNA expression of the Δ40, Δ133, β and γ p53 isoforms in 6 breast cancer cell lines and 148 invasive breast cancers in relation to clinicopathological features to determine those that are likely to have clinical significance in this disease.
The relative expression of Δ40p53 in breast cancer has not previously been analysed at either the mRNA or the protein level in clinical breast cancer specimens. Our study has shown for the first time that Δ40p53 was the most highly expressed isoform at the mRNA level in breast cancer, expressed at levels almost 50-fold higher than the least expressed isoform p53γ. Moreover, Δ40p53 was significantly higher in breast tumour tissue when compared with that of matched NAT, suggesting that it may be involved in tumour development. We also showed that Δ40p53 was the only isoform that was significantly associated with hormone receptor expression. Δ40p53 expression was significantly higher in triple-negative breast cancer (TNBC) and in HER2-negative cases overall (regardless of ER/PR). TNBC is characterized by an absence of ER, PR and HER2 (39, 40) . Although TNBCs comprise only 10-24% of all breast cancers, patients who are diagnosed with TNBC are of younger age, tend to develop tumours of larger size and have an increased likelihood of distant metastasis and death within 5 years (39, 40) . Thus, TNBC is a clinically aggressive subtype, for which there are no current targeted therapies. The clinical relevance of high Δ40p53 expression in TNBC is unclear and we were unable to validate this finding in an independent set of TNBCs as we were unable to obtain p53 mutation status from this set of patients. This result must be validated in a larger cohort with p53 mutation status to truly determine the significance of this finding. High Δ40p53 mRNA expression levels have been shown to be an independent prognostic indicator in mucinous ovarian cancer, associated with lower rates of recurrence, and this was not observed for other ovarian cancer subtypes (28) . It is possible that Δ40p53 may be an independent prognostic indicator in the TNBC subtype specifically; however, we were unable to examine this in this study due to the small number of TNBC cases (n = 19). The functional role of high levels of Δ40p53 in breast cancer as identified in this study remains to be determined and is the subject of ongoing investigation. Δ40p53 is an N-terminal truncation of WTp53 that lacks the first transcriptional activation domain, but retains the second transcriptional activation domain and is capable of homo-and hetero-oligomerization (33, 38) . Initial reports suggested that Δ40p53 had no activity on its own (18, 33) , and subsequently, that it acted as a dominant-negative inhibitor of p53-mediated transactivation, growth suppression and apoptosis (18, 33) . It is now apparent that its functions are far more complex. Δ40p53 has been shown to alter p53 target gene expression in both a positive and negative manner to modulate the biological outcome of WTp53 activation. The functional impact of Δ40p53 appears to be intricately related to its relative levels and on the cellular context (19, 20, 34, 38, 41) . In a recent study conducted by Hasfi et al. (34) , it was shown that when expressed at levels higher than that of p53, Δ40p53 exerts an inhibitory effect on p53 function. However, at levels lower than or equivalent to p53, Δ40p53 acted as an enhancer or an inhibitor of p53 transcriptional activity, depending on the cell line under study (34) . It was proposed that these contradictory effects are due to Δ40p53 modulating p53 activity in two distinct ways: (i) by altering the binding of basal transcription machinery to the Δ40p53/ p53 heterotetramer, thereby decreasing transcriptional activity and (ii) by interfering with MDM-2 binding to p53, Δ40p53 can protect p53 from MDM-2-mediated proteasomal degradation, thus enhancing p53 activity (34) . In this regard, it is clear that even at levels lower than p53, as observed in this study (Figure 2A ), Δ40p53 can still modulate p53 activity. The functional and somewhat paradoxical impact of altered Δ40p53 levels has been demonstrated in several recent studies. Overexpression of Δ40p53 has recently been shown to increase the amount of endogenous p53 and to increase apoptosis in human melanoma cells, in part, by modulating the transcription of downstream target genes including downregulation of p21 and upregulation of p53-induced death domain protein, to favour apoptosis rather than cell cycle arrest (42) . Δ40p53 has been shown to play critical roles in the mouse at all developmental stages (43, 44) . In the developing embryo, the expression of Δ40p53 is detected well before WTp53, and in embryonic stem cells, Δ40p53 is required for the maintenance of a highly proliferative pluripotent state (43) . In contrast, overexpression of Δ40p53 in somatic cells leads to p53-dependent senescence and premature aging (44) . Thus, although Δ40p53 has opposing roles in embryonic and somatic cells, it is clear that proper control of the ratio of WTp53 to Δ40p53 is absolutely required for normal cell growth and proliferation. Δ40p53 also has functions that are independent of WTp53, such as induction of G 2 arrest, and has been shown to transcriptionally activate targets such as 14-3-3σ to a greater extent than WTp53 in response to cellular stress (20, 38, 45) .
The p53 isoforms p53β, p53γ and Δ133p53 have been reported to be expressed in a range of malignancies including melanoma, ovarian cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, acute myeloid leukaemia, colon cancer and breast cancer (16, (21) (22) (23) (24) (25) 28, 46) . Both p53β and p53γ have been demonstrated to enhance tumour growth of p53 null cells in vivo; although Δ133p53 can also perpetuate tumour growth, it appears to have additional roles in stimulating angiogenesis and inflammation and can promote tumour invasion and metastasis in mouse models (47) (48) (49) . In this study, we examined whether the relative expression of these p53 isoforms was associated with clinical features of breast cancer. We have shown that the relative expression of p53γ was associated with grade, whereas p53β was negatively associated with tumour size. p53β was also associated with age of disease onset, but only when analysis was confined to Grade 3 tumours. This is consistent with the findings of Fujita et al. (22) , who found decreased expression of p53β in colon cancers of increasing severity (adenoma → carcinoma), but in contrast to Song et al. (24) , who found p53β positively associated with tumour grade in renal cell carcinoma (22, 24) . This suggests that the role of p53β in cancer may depend on the site of the cancer. Additionally, we did not observe an association of p53γ with mutation status, nor did we observe an association of p53β with ER status as previously reported by Bourdon et al. (26) . This may be in part because of the differences in study design. Although the proportion of breast tumours that were Grade 3 (51%) or LN positive (53%) in our study was similar to the proportion of breast tumours that were Grade 3 (48%) or LN positive (49.6%) in their study, Bourdon et al. (26) used nested PCR to examine the entire coding region of the p53β and p53γ transcripts, classing transcript expression as either present or absent. In contrast, our study used semi-quantitative PCR to examine N-and C-terminal variations of p53 mRNA, resulting in a relative expression level of each of the isoforms (Δ40, Δ133, β, γ), which was used in our correlation analysis (the limitations of this are discussed below). Δ133p53 has previously been reported to be expressed in the majority of breast cancers and to be inversely associated with the RNA helicase p68, but its potential clinical significance is not known (16, 27) . In our study, Δ133p53 was one of the least expressed isoforms and no associations with the clinical features examined were found, arguing against this isoform having major clinical significance in breast cancer. Perhaps one of the most clinically important findings from this study was the association of p53β with disease-free survival. High relative expression levels of p53β were associated with significantly lower levels of recurrence compared with patients expressing low levels of p53β. This is concordant with our finding of a negative association between p53β expression levels and tumour grade. Furthermore, p53β expression has been positively associated with long-term survival in acute myeloid leukaemia, providing further support for our findings (21) . Additionally, we found that patients expressing low levels of p53β and harbouring a mutation in p53 had the worst prognosis, whereas patients expressing high levels of p53β who also had p53 isoforms in breast cancer a mutation in p53 had a similar prognosis to patients who did not have a p53 mutation. This is in contrast to the results of Bourdon et al. (26) , who found a similar association with p53γ, but saw no significant association of p53β with disease-free survival. As stated previously, the proportion of breast tumours that were of high grade or LN positive were comparable between our study and theirs, and thus, this cannot explain the differences between these results (26) . Our results suggest that high expression of p53β may be protective in breast cancer metastasis and that it may provide further stratification for disease prognoses. Furthermore, it may offer some explanation for the discrepancies between p53 mutation status and prognosis in the literature (36) . How high levels of p53β could provide protection against recurrence is not known. p53β has been reported to act as an enhancer of p53 function on a subset of target genes (16, 25) . Although endogenously expressed p53 and p53β have been shown to interact with one another, it is also likely that this isoform has functions that are independent of p53, given that it can bind to DNA in the absence of p53 (16) . In this regard, p53β has been demonstrated to enhance chemosensitivity in p53 null H1299 cells (48, 50) . Some clues as to its protective function against cancer progression are provided by the recent study of Fujita et al. (22) , where modulation of p53 activity by p53β overexpression resulted in replicative senescence. A limitation of our study design is that the p53 isoforms were analysed at the RNA level rather than the protein level in clinical specimens. Currently, there are no antibodies that can specifically detect the p53 isoforms by immunohistochemistry and western blot analysis requires a range of p53 antibodies to identify the isoforms; and even then, the molecular weights are still very similar to that of the WT protein leaving some level of uncertainty with this type of analysis. RT-PCR represents the only method by which the p53 isoforms can be specifically detected with certainty. Although our analysis was highly advantageous for detecting relative differences in the mRNA production of these Nand C-terminal variants, one disadvantage is that we are unable to differentiate between the full-length variant (i.e. Δ40p53, Δ133p53, p53γ, p53β) or its truncated variants (i.e. Δ40p53β, Δ40p53γ, Δ133p53β, Δ133p53γ) due to restrictions in amplicon length used for real-time PCR. However, the fact that the relative expression levels of the individual isoforms were several fold different between one another (Figure 1) , and in individual patients (data not shown), would argue against these results being due to combinations of N-and C-terminal truncations and would suggest that they are more likely to be the full-length variants (i.e. an N-or C-terminal truncation, not both).
Nevertheless, this report provides critical information on the mRNA expression of the N-and C-terminal isoforms. Although the expression of all the isoforms examined was highly correlated with one another in individual tumours ( Supplementary Table S3 , available at Carcinogenesis Online), the relative levels of the individual isoforms varied greatly, with Δ40p53 having significantly higher expression in the large majority of tumours compared with any other isoform examined in this study. The regulation of Δ40p53 at the mRNA level has not been intensively studied, with only one report to date. Marcel et al. (51) have shown that G-quadruplex regulatory motifs in intron 3 can regulate the expression of the Δ40p53 transcript, with mutations of this motif causing retention of intron 2 and leading to the production of Δ40p53 mRNA. We identified a polymorphism in intron 3 present in the majority of tumours in our study ( Supplementary Table  S4 , available at Carcinogenesis Online) that may alter this motif and could be responsible for the high levels of Δ40p53 mRNA observed in the tumours analysed. We cannot rule out the possibility that this polymorphism is present in constitutional DNA and, therefore, is not tumour specific. Although Δ40p53 can also be produced by alternative translation (18, 33) , our results confirmed that high levels of Δ40p53 were present at the protein level in breast cancer cell lines at levels comparable with that of the mRNA (Figure 2) suggesting that alternative splicing is a major route of Δ40p53 production in breast cancer cells. Furthermore, Δ40p53 protein was present at much higher levels in breast cancer cells than observed in benign breast epithelial cells suggesting that it is indeed relevant to the modulation of the p53 tumour suppressive properties.
In conclusion, this study has analysed the relative expression of p53 mRNA variants in breast cancer and examined their relationship to clinicopathological features to determine those that are likely to have clinical significance in this disease. We have found several potentially important clinical associations particularly with Δ40p53 mRNA, which was the most highly expressed isoform and was significantly associated with an aggressive breast cancer subtype-TNBC, whereas p53β was significantly negatively associated with tumour size and positively associated with metastasis-free survival. These results have implications for the stratification of breast cancer based on p53 functional activity.
